RARA CRAFT DATABASE for FDA Medical Devices

FDA Guidance and Notices, December 2025: Final Guidance on Real-World Evidence for Devices and QMSR Technical Amendments

日本語版

For device regulatory teams, the December 2025 document to read first is FDA's final guidance on using real-world evidence (RWE) to support regulatory decisions on medical devices, issued on the 18th. Earlier in the month FDA issued final guidance on the eCopy program for device submissions, and on December 4 it published technical amendments that bring related regulations in line with the Quality Management System Regulation (QMSR). They add nothing new and take effect February 2, 2026.

On the digital health side, a December 8 notice announced TEMPO (Technology-Enabled Meaningful Patient Outcomes), a pilot that works alongside the ACCESS Model of the Centers for Medicare & Medicaid Services (CMS). On December 29, FDA published a petition seeking a conditional 510(k) exemption for radiology software that helps with detection, diagnosis and triage, with comments due February 27, 2026.

Final guidance

Draft guidance

In the Federal Register

Device classification rules

Most of these write a classification decided earlier into the regulations; they do not mean any individual product was authorized that day. "Reclassification" changes a device type's class, and "proposed" marks a proposed rule open for comment.

Safety communications and other updates

Also this month

  • December 10: A CDRH webinar used polytetrafluoroethylene (PTFE) as a case study in material substitutions for devices subject to 510(k).
  • December 16: FDA held a webinar on key takeaways from the QMSR.

Note: dates are FDA issue dates or Federal Register publication dates. Linked pages may now show a later version.

RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.

← All articles